
METRO REPORTS 2025 THIRD QUARTER RESULTS Français
2025 THIRD QUARTER HIGHLIGHTS
Sales of $6,871.0 million, up 3.3%
Food same-store sales (1) up 1.9%
Pharmacy same-store sales (1) up 5.5%
Net earnings of $323.0 million, up 9.0% and adjusted net earnings (1) of $331.8 million, up 8.8%
Fully diluted net earnings per share of $1.48, up 13.0% and adjusted fully diluted net earnings per share (1) of $1.52, up 12.6%
16 weeks / Fiscal Year
(Millions of dollars, except for net earnings per share)
2025
%
2024
%
Change (%)
Sales
6,871.0
100.0
6,651.8
100.0
3.3
Operating income before depreciation and amortization
and impairments of assets
655.7
9.5
620.2
9.3
5.7
Net earnings
323.0
4.7
296.2
4.5
9.0
Fully diluted net earnings per share
1.48
—
1.31
—
13.0
Adjusted net earnings (1)
331.8
4.8
305.0
4.6
8.8
Adjusted fully diluted net earnings per share (1)
1.52
—
1.35
—
12.6
40 weeks / Fiscal Year
(Millions of dollars, except for net earnings per share)
2025
%
2024
%
Change (%)
Sales
16,898.0
100.0
16,281.5
100.0
3.8
Operating income before depreciation and amortization
and impairments of assets
1,598.2
9.5
1,527.4
9.4
4.6
Net earnings
802.5
4.7
711.8
4.4
12.7
Fully diluted net earnings per share
3.63
—
3.13
—
16.0
Adjusted net earnings (1)
803.8
4.8
746.4
4.6
7.7
Adjusted fully diluted net earnings per share (1)
3.64
—
3.28
—
11.0
PRESIDENT'S MESSAGE
"We are pleased with our results in the third quarter, marked by solid comparable sales growth in food and pharmacy, and good cost control. We successfully opened 5 new food stores in the quarter, a pace that will continue (2) in the fourth quarter, on track with our plan to accelerate the development of our growing discount banners. We are confident that our sustained investments in our retail network and supply chain combined with strong execution will continue to fuel our growth and create long-term shareholder value (2)", declared Eric La Flèche, President and Chief Executive Officer.
SALES
Sales in the third quarter of Fiscal 2025 ended on July 5, 2025 were $6,871.0 million, up 3.3% versus the third quarter of the prior year which ended on July 6, 2024, driven by higher sales in our retail network.
Food same-store sales (1) were up 1.9% in the third quarter of Fiscal 2025 (2024 — 2.4%). Online food sales (1) were up 14.4% versus last year (2024 — 34.3%). Our food basket inflation was generally in line with the reported CPI for food purchased from stores. Pharmacy same-store sales (1) were up 5.5% (2024 — 5.2%), with a 6.2% increase in prescription drugs (1) and a 4.0% increase in front-store sales (1), primarily driven by over-the-counter products, cosmetics, and health and beauty.
Sales in the first 40 weeks of Fiscal 2025 totalled $16,898.0 million, up 3.8% compared to $16,281.5 million for the corresponding period of 2024.
This earnings measurement excludes financial costs, taxes, depreciation and amortization and impairments of assets.
Operating income before depreciation and amortization and impairments of assets for the third quarter of Fiscal 2025 totalled $655.7 million, or 9.5% of sales, an increase of 5.7% versus the corresponding quarter of Fiscal 2024. Operating income before depreciation and amortization and impairments of assets for the first 40 weeks of Fiscal 2025 totalled $1,598.2 million, or 9.5% of sales, up 4.6% versus the corresponding period of 2024. The first 40 weeks of Fiscal 2024 benefited from a gain on sale of assets of $6.7 million.
Gross margin (1) for the third quarter and the first 40 weeks of Fiscal 2025 was 19.8% versus 19.6% and 19.7% for the corresponding periods of 2024. The margin improvement in the quarter is partly attributable to productivity gains at our food distribution centers and a reduction in shrink.
Operating expenses as a percentage of sales for the third quarter of Fiscal 2025 were 10.2%, the same rate as in the corresponding quarter of 2024. For the first 40 weeks of Fiscal 2025, operating expenses as a percentage of sales were 10.4% versus 10.3% for the corresponding period of 2024. The increase in operating expenses for the 40-week period ended on July 5, 2025 is mainly due to the launch of the Moi Rewards program in Ontario in the first quarter of 2025, fees related to higher online partnership sales and the recording of professional fees regarding the resolution of a tax position related to prior years.
DEPRECIATION AND AMORTIZATION
Total depreciation and amortization expense for the third quarter of Fiscal 2025 was $184.9 million versus $174.0 million for the corresponding quarter of 2024. For the first 40 weeks of Fiscal 2025, total depreciation and amortization expense was $454.6 million versus $434.6 million for the corresponding period of 2024. The increase in depreciation and amortization expense is mainly due to the timing of retail investments and the commissioning of investments in our supply chain, including some automation technology in the Pharmacy division and the final phase of our fresh distribution centre in Toronto last summer.
IMPAIRMENTS OF ASSETS
During the second quarter of Fiscal 2024, the Corporation recorded $20.8 million of impairments of assets resulting from the decision to have Metro stores in Ontario withdraw from the Air Miles® loyalty program in the summer of 2024. This impairment represents the entire carrying value of the loyalty program asset.
NET FINANCIAL COSTS
Net financial costs for the third quarter of Fiscal 2025 were $45.3 million compared with $46.6 million for the corresponding quarter of 2024. For the first 40 weeks of Fiscal 2025, net financial costs were $109.4 million compared with $113.1 million for the corresponding period of 2024. The decrease in financial costs is mainly due to lower interest expense on net debt partly offset by lower capitalized interest.
INCOME TAXES
The income tax expense of $102.5 million for the third quarter of Fiscal 2025 represented an effective tax rate of 24.1% compared with an income tax expense of $103.4 million and an effective tax rate of 25.9% for the third quarter of Fiscal 2024. The decrease in the effective tax rate in 2025 is mainly attributable to a provincial tax holiday related to the commissioning of our new automated distribution center for fresh and frozen products in Terrebonne.
The 40-week period income tax expense of $231.7 million for Fiscal 2025 and $247.1 million for Fiscal 2024 represented effective tax rates of 22.4% and 25.8% respectively. The decrease in the effective tax rate in 2025 is mainly attributable to a $20.6 million income tax adjustment in respect of prior years and a provincial tax holiday related to the commissioning of our new automated distribution center for fresh and frozen products in Terrebonne. The total tax holiday represents approximately $66 million and we estimate it will be recognized over a period of 3 years (2).
NET EARNINGS AND ADJUSTED NET EARNINGS (1)
Net earnings for the third quarter of Fiscal 2025 were $323.0 million compared with $296.2 million for the corresponding quarter of 2024, while fully diluted net earnings per share were $1.48 compared with $1.31 in 2024, up 9.0% and 13.0% respectively. Excluding the specific item shown in the table below, adjusted net earnings (1) for the third quarter of Fiscal 2025 totalled $331.8 million compared with $305.0 million for the corresponding quarter of 2024, and adjusted fully diluted net earnings per share (1) for third quarter of Fiscal 2025 were $1.52, versus $1.35 in 2024, up 8.8% and 12.6% respectively.
Net earnings for the first 40 weeks of Fiscal 2025 were $802.5 million compared with $711.8 million for the corresponding period of 2024, while fully diluted net earnings per share were $3.63 compared with $3.13 in 2024, up 12.7% and 16.0% respectively. Excluding the specific items shown in the table below, adjusted net earnings (1) for the first 40 weeks of Fiscal 2025 totalled $803.8 million compared with $746.4 million for the corresponding period of 2024, and adjusted fully diluted net earnings per share (1) amounted to $3.64 versus $3.28, up 7.7% and 11.0% respectively.
40 weeks / Fiscal Year
2025
2024
Change (%)
Net earnings
(Millions of
dollars)
Fully diluted
EPS (Dollars)
Net earnings
(Millions of
dollars)
Fully diluted
EPS
(Dollars)
Net earnings
Fully
diluted
EPS
Per financial statements
802.5
3.63
711.8
3.13
12.7
16.0
Loss on impairment of a loyalty program, net
of taxes of $2.7
—
18.1
Gain on disposal of an investment in an
associate, net of taxes of $1.6
—
(5.4)
Amortization of intangible assets acquired in
connection with the Jean Coutu Group
acquisition, net of taxes of $7.8
21.9
21.9
Favorable resolution of a tax position in
respect of prior years
(20.6)
—
Adjusted measures (1)
803.8
3.64
746.4
3.28
7.7
11.0
NORMAL COURSE ISSUER BID PROGRAM
Under the current normal course issuer bid program, the Corporation may repurchase up to 10,000,000 of its Common Shares between November 27, 2024 and November 26, 2025. Between November 27, 2024 and August 1, 2025, the Corporation has repurchased 5,700,000 Common Shares at an average price of $98.55, for a total consideration of $561.8 million.
On August 12, 2025, the Board of Directors declared a quarterly dividend of $0.37 per share, the same amount declared last quarter.
FORWARD-LOOKING INFORMATION
We have used, throughout this report, different statements that could, within the context of regulations issued by the Canadian Securities Administrators, be construed as being forward-looking information. In general, any statement contained herein that does not constitute a historical fact may be deemed a forward-looking statement. Expressions such as "continue", "estimate", "predict" and other similar expressions are generally indicative of forward-looking statements. The forward-looking statements contained herein are based upon certain assumptions regarding the Canadian food and pharmaceutical industries, the general economy, our annual budget, as well as our 2025 action plan.
These forward-looking statements do not provide any guarantees as to the future performance of the Corporation and are subject to potential risks, known and unknown, as well as uncertainties that could cause the outcome to differ significantly. Risk factors that could cause actual results or events to differ materially from our expectations as expressed in, or implied by, our forward-looking statements are described and discussed under the "Risk Management" section in our Annual Report 2024.
We believe these statements to be reasonable and pertinent as at the date of publication of this report and represent our expectations. The Corporation does not intend to update any forward-looking statement contained herein, except as required by applicable law.
NON-GAAP AND OTHER FINANCIAL MEASUREMENTS
In addition to the International Financial Reporting Standards (IFRS) measurements provided, we have included certain non-GAAP and other financial measurements. These measurements are presented for information purposes only. They do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measurements presented by other public companies.
National Instrument 52-112 Non-GAAP and Other Financial Measures Disclosure sets out specific disclosure requirements for non-GAAP financial measures, non-GAAP ratios, and other financial measures, which are capital management measures, supplementary financial measures, and total of segments measures, as defined in the Instrument (together the "specified financial measures").
The specified financial measures we disclose in our documents made available to the public are presented by measurement categories below.
NON-GAAP FINANCIAL MEASURES
Adjusted earnings before net financial costs and income taxes is a non-GAAP financial measurement that, with respect to its composition, is adjusted to exclude net financial costs and special items from the composition of the most directly comparable financial measure disclosed in our consolidated financial statements, which is earnings before income taxes. Special items may include acquisition and restructuring charges, gains or losses on the disposal of investments, and amortization and impairment losses of intangible assets resulting from a business acquisition.
Adjusted net earnings is a non-GAAP financial measurement that, with respect to its composition, is adjusted to exclude special items from the composition of the most directly comparable financial measure disclosed in our consolidated financial statements, which is net earnings. Special items may include acquisition and restructuring charges, gains or losses on the disposal of investments, amortization and impairment losses of intangible assets resulting from a business acquisition, and significant prior-year tax adjustments.
For measurements depicting financial performance, we believe that presenting earnings adjusted for these items, which are not necessarily reflective of the Corporation's performance, leaves readers of financial statements better informed thus enabling them to better perform trend analysis, evaluate the Corporation's financial performance and assess its future outlook. Adjusting for these items does not imply that they are non-recurring.
NON-GAAP RATIOS
Adjusted fully diluted net earnings per share is a non-GAAP ratio by where a non-GAAP financial measure is used as one or more of its components. The non-GAAP component used is adjusted net earnings (1). Adjusted fully diluted net earnings per share is calculated by dividing the adjusted net earnings (1) attributable to equity holders of the parent by the weighted average number of Common Shares outstanding during the year, adjusted to reflect all potential dilutive shares.
We believe that presenting this ratio, in which a non-GAAP financial measurement is used as one or more of its components, leaves readers of financial statements better informed as to the current period and corresponding prior year's period's performance, thus enabling them to better perform trend analysis, evaluate the Corporation's financial performance and assess its future outlook. Adjusting for these items does not imply that they are non-recurring.
SUPPLEMENTARY FINANCIAL MEASURES
The supplementary financial measures listed below are, or are intended to be, disclosed on a periodic basis to depict the historical or expected future financial performance, financial position or cash flow of the Corporation.
Food same-store sales are defined as comparable retail sales of stores with more than 52 consecutive weeks of operations, including relocated, expanded and renovated locations. Food same-store sales is a measure based on all stores in our network, including those whose sales are not included in the Corporation's consolidated financial statements.
Online food sales are the sum of sales made from all our online channels.
Pharmacy same-store sales (including total, front-store and prescription drugs) are defined as comparable retail sales of stores with more than 52 consecutive weeks of operations, including relocated, expanded and renovated locations. Pharmacy same-store sales do not form part of the Corporation's consolidated financial statements because the pharmacies are held by pharmacist owners.
Gross margin ratio is calculated by dividing gross profit by sales.
The significant investments in the modernization of our supply chain are largely behind us, and we are now focussed on realizing efficiency gains. These investments position us well for growth through the expansion of our retail network in the years ahead. As we begin our fourth quarter, we continue to face an uncertain economic environment, and it is difficult to predict how this environment will evolve and how it will impact our operations and our customers. We remain steadfast in our focus to deliver value to our customers through our robust merchandising programs, our strong private label and loyalty offers and working with our supply chain partners.
CONFERENCE CALL
Financial analysts and institutional investors are invited to participate in a conference call for the 2025 third quarter results at 9:00 a.m. (EDT) today, August 13, 2025. To access the conference call, please dial 1 (800) 990-4777. The media and investing public may access this conference via a listen mode only.
Notice to readers: METRO INC. third quarter of 2025 interim condensed consolidated financial statements and management's discussion and analysis are available on the Internet at www.corpo.metro.ca - Corporate Site - Investors - 2025 Quarterly Results - 2025 Third Quarter Results.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
21 minutes ago
- Cision Canada
HR Path Strengthens Global Presence with Strategic Acquisition of RKM Consulting in Australia
PARIS, /CNW/ -- HR Path, a global leader in HR consulting and HRIS solutions, is proud to announce its strategic acquisition of RKM Consulting, an Australian based company specialized in advising & implementing HRIS systems, with a strong focus on SAP SuccessFactors. View PDF With a presence in 28 countries and a team of over 2,500 professionals, HR Path is a trusted partner for businesses navigating the complexities of Human Resources. Specializing in advisory, implementation, and operational services, HR Path delivers cutting-edge solutions designed to enhance efficiency and foster growth. Since its founding in 2001, the company has remained steadfast in its mission to transform HR practices globally. Founded in 2000, RKM Consulting has built a strong reputation for delivering customer-focused HR Technology solutions. RKM was formed with the focus on partnering with the HR customer community to ensure that their HR Technology solutions are delivered successfully. RKM Consulting's business of human resources technology services, specializes in collaborating with clients to deliver human resources information systems ("HRIS") solutions and supporting those HRIS solutions in the selection, implementation delivery, and the business-as-usual user environment of its customers. This acquisition represents a significant milestone for HR Path, solidifying its position as a leader in the HR industry and expanding its presence in the Australian/New Zealand market. RKM Consulting's specialized focus on HRIS technology, in particular SAP SuccessFactors, reinforces HR Path's already well-established position in the SAP HCM market and further supports its commitment to driving organizational growth and excellence through strategic HR solutions. HR Path has been active in Australia since 2019 through the acquisition of DDG, and the opening of our Australian office in 2024 marked a renewed commitment to the region. RKM Consulting's customer centric focus on HRIS technology, perfectly complements HR Path's vision of driving organizational growth and excellence through strategic HR solutions. "We're thrilled to welcome RKM Consulting to the HR Path family. This acquisition is a significant milestone for our growth journey in Australia and New Zealand," said Suraj K. K., Managing Director of HR Path ANZ. "We are excited about this new chapter!" said Rob Makinson, Managing Director at RKM Consulting. " This step opens exciting opportunities for our team, clients and provides a platform for our continued growth and success. We will maintain our commitment to delivering exceptional customer service within the Australian HR Business Community while exploring new possibilities within HR Path." Fabienne LATOUR - + 33 650 10 10 29


Cision Canada
21 minutes ago
- Cision Canada
Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden
Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with ease LONDON, Aug. 14, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals navigate complex and evolving global requirements with greater ease, speed and confidence. Informed by customer input and tested with industry partners, the beta version of the Regulatory Assistant is built to meet the real-world needs of regulatory professionals across biopharma, medtech and research organizations. The Regulatory Assistant will be launched to all Cortellis Regulatory Intelligence users in September with additional capabilities designed to further enhance usability, personalization and decision support. Features within the Beta version of Cortellis Regulatory Intelligence AI Assistant include: Conversational AI with referenced answers: Users can ask regulatory questions naturally and get precise, cited responses, saving hours of manual work. The AI-powered Assistant, guided by domain expertise, understands regulatory nuances to provide customers with accurate answers. Your conversations, always within reach: Users can pick up right where they left off with chat history, resulting in more relevant, personalized responses. Multilingual by design: Search and interact in preferred languages for a seamless, tailored experience. Yuval Kiselstein, VP, R&D, Life Sciences & Healthcare at Clarivate, said: "Today's regulatory environment is increasingly complex and fast-changing. The beta launch of the Regulatory Assistant is a key milestone in our mission to empower regulatory teams with intuitive, AI-driven tools that enhance productivity and support confident, compliant decision-making. By working closely with our Collaborative Partners, we are building a solution that reflects real-world workflows and priorities." Janeen Skutnik-Wilkinson, Director, Regulatory Intelligence & External Engagement, Moderna, said: "We are so pleased to be a part of the beta testing for the new AI Regulatory assistant. This tool will save us significant time and resources compared to searching manually, and we are already seeing how this will speed up internal enquiries and intelligence work. We have been impressed with how the team is actively engaging clients in the development process by seeking out and acting upon our feedback to continually improve the product. They are dedicated to building a useful tool that meets our needs while ensuring that it is also accurate and user-friendly." With market-leading intelligence solutions, transformative data technologies and trusted AI, Clarivate equips customers with the insight and foresight they need across every stage of the product lifecycle, from early discovery through commercialization and beyond. In line with this commitment, the new AI-powered Regulatory Assistant brings the Clarivate mission to life by helping customers navigate complexity, accelerate decision-making and shape the future of healthcare. As regulatory professionals face mounting pressure to keep pace with global changes, interpret complex requirements, and ensure compliance, the Regulatory Assistant streamlines access to trusted intelligence, enabling faster, more confident decisions. Built on the same proven Clarivate AI platform that powers Clarivate solutions, including Web of Science, and trusted by hundreds of organizations, it combines powerful technology with 30+ years of regulatory expertise relied on by top pharma and global agencies. To learn more about the Cortellis Regulatory Intelligence AI-powered Regulatory Assistant, visit here. Media Contact: Catherine Daniel Director, External Communications, Life Sciences & Healthcare Clarivate [email protected]


Toronto Star
an hour ago
- Toronto Star
Cornish Metals Releases Unaudited Financial Statements and Management's Discussion and Analysis for the Six Months Ended 30 June 2025
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Cornish Metals Inc. (TSX-V/AIM: CUSN) ('Cornish Metals' or the 'Company'), a mineral exploration and development company focused on advancing its wholly owned and permitted South Crofty tin project in Cornwall, United Kingdom, is pleased to announce that it has released its unaudited financial statements and management, discussion and analysis ('MD&A') for the six months ended June 30, 2025. The reports are available under the Company's profile on SEDAR+ ( and on the Company's website (